Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Outlines Internal ANDA Refuse-To-Receive Policy

Executive Summary

Manual of Policies and Procedures document should provide more help to sponsors on what items must be in an ANDA for it to be reviewed.

You may also be interested in...

US FDA Largely Stands Pat In Revised ANDA Submission Guidance

Agency made few of industry's requested changes regarding when it would refuse to receive generic applications, but the absence of comments from several big generics companies indicates some level of satisfaction.

Generic Reviews Steaming Ahead, But Are Storm Clouds On The Horizon?

FDA's generic office director notes a jump in year-end submissions – and a jump in refuse-to-receive actions.

ANDA Refuse-to-Receive Challenges Become More Common – And More Successful

Teva official calls for improved staff consistency as a new GDUFA headache emerges for FDA.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts